SK Bioscience

SK Bioscience is a subsidiary of South Korean conglomerate SK Group and focuses on the discovery and production of vaccines. The vaccine research and production company was spun out from SK Chemicals in 20152018.

The company researched and developed a medical solution for COVID-19 using a monoclonal antibody treatment candidate. The company has a manufacturing plant that can produce vaccines for the virus once they have been approved by the appropriate governing bodies.

In 2006, SK Bioscience began research for a self-developed vaccine. In 2014, the company signed an agreement with Sanofi Pasteur SA for joint R&D and the sale of next-generation’s pneumococcal conjugate vaccinepneumococcal conjugate vaccine (PCV).

SK Bioscience is a subsidiary of South Korean conglomerate SK Group and focuses on the discovery and production of vaccines. The vaccine research and production company was spun out from SK Chemicals in 2015.

SK Bioscience has technology capabilities in R&D and manufacturing.

Its research and development technologies include suspension cell culture, conjugation technology, and reverse genetic technologies. Its main production facility L HOUSE, located in Andong Gyeongbuk Bio Industrial Complex, uses single-use bags in its bioreactor, rather than conventional stainless steel tanks.

In 2006, SK Bioscience began research for a self-developed vaccine. In 2014, the company signed an agreement with Sanofi Pasteur SA for joint R&D and the sale of next-generation’s pneumococcal conjugate vaccine (PCV).

It also developed other vaccine products, including Korea’s first cell culture-derived trivalent influenza vaccine (2014) and the world’s first cell culture-derived quadrivalent influenza vaccine (2015).

It has acquired marketing approval for “SKYZOSTER”, a shingles vaccine (2017), and SKY Varicella, a varicella vaccine (2018).